Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epidemiology of antimicrobial resistance in commensal E. coli from healthy dairy cattle on a Mediterranean pasture-based system of Australia: A cross-sectional study.

Autor: Tree M; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia. Electronic address: michele.tree@outlook.com., Lam TJGM; GD Animal Health, Deventer, and Faculty of Veterinary Medicine Utrecht University, The Netherlands., McDougall S; Cognosco, Anexa Veterinary Services, PO Box 21, Morrinsville 3340, New Zealand., Beggs DS; Animal Welfare Science Centre, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria 3052, Australia; Faculty of Veterinary and Agricultural Sciences, University of Melbourne, 250 Princes Highway, Werribee, Victoria 3030, Australia., Robertson ID; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia., Barnes AL; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia. Electronic address: A.Barnes@murdoch.edu.au., Chopra A; Institute for Immunology and Infectious Diseases, 390, Discovery Way, Murdoch University 6150, Western Australia, Australia., Ram R; Institute for Immunology and Infectious Diseases, 390, Discovery Way, Murdoch University 6150, Western Australia, Australia., Stockman CA; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia., Kent TC; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia., Aleri JW; School of Veterinary Medicine, College of Science, Health, Engineering and Education, Murdoch University, 90 South Street, Murdoch 6150, Western Australia, Australia; Centre for Animal Production and Health, Future Foods Institute, Murdoch University, 90 South Street, Murdoch, 6150 WA, Australia; Harry Butler Institute, Murdoch University, 90 South Street, Murdoch, 6150 WA, Australia.

Publikováno v: Journal of dairy science [J Dairy Sci] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.

Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.

Autor: Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health and Care Research (NIHR), Leeds Biomedical Research Centre, Leeds, UK., Pavelka K; Institute of Rheumatology, Charles University, Prague, Czech Republic., Hsieh SC; International Medicine, National Taiwan University Hospital, Taipei, Taiwan., Bonnington TL; Medical, AbbVie Ltd, Chicago, IL, USA., Kent TC; Medical, AbbVie Ltd, Chicago, IL, USA., Marchbank K; Medical, AbbVie Ltd, Chicago, IL, USA., Edwards CJ; NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Publikováno v: Rheumatology advances in practice [Rheumatol Adv Pract] 2023 Feb 08; Vol. 7 (1), pp. rkad017. Date of Electronic Publication: 2023 Feb 08 (Print Publication: 2023).

The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response.

Autor: Roberts MJ; School of Life Sciences, University of Nottingham, Nottingham, UK., Broome RE; Novartis Institutes for Biomedical Research, Horsham, UK., Kent TC; Novartis Institutes for Biomedical Research, Horsham, UK., Charlton SJ; School of Life Sciences, University of Nottingham, Nottingham, UK.; Novartis Institutes for Biomedical Research, Horsham, UK., Rosethorne EM; School of Life Sciences, University of Nottingham, Nottingham, UK. elizabeth.rosethorne@nottingham.ac.uk.; Novartis Institutes for Biomedical Research, Horsham, UK. elizabeth.rosethorne@nottingham.ac.uk.

Publikováno v: Respiratory research [Respir Res] 2018 Apr 07; Vol. 19 (1), pp. 56. Date of Electronic Publication: 2018 Apr 07.

Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action.

Autor: Bradley ME; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Dombrecht B; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.) steven.charlton@nottingham.ac.uk bruno.dombrecht@ablynx.com., Manini J; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Willis J; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Vlerick D; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., De Taeye S; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Van den Heede K; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Roobrouck A; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Grot E; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Kent TC; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Laeremans T; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Steffensen S; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Van Heeke G; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Brown Z; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.)., Charlton SJ; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.) steven.charlton@nottingham.ac.uk bruno.dombrecht@ablynx.com., Cromie KD; Novartis Institutes for Biomedical Research, Horsham, West Sussex, United Kingdom (M.E.B., J.M., J.W., E.G., T.C.K., G.V.H., Z.B., S.J.C.); Ablynx NV, Zwijnaarde, Belgium (B.D., D.V., S.D.T., K.V.H., A.R., S.S., K.D.C.); and Structural Biology Research Center, Vlaams Instituut voor Biotechnologie, Brussels, Belgium (T.L.).

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2015 Feb; Vol. 87 (2), pp. 251-62. Date of Electronic Publication: 2014 Dec 02.